Credit: Getty Images This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.
Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
Federal data indicate that over half the US population aged 6-46 years is infected with cytomegalovirus (CMV), typically spread through bodily fluids. Most people have mild or no negative effects from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results